Last update 30 May 2026

GEN-1044

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
DuoBody-CD3x5T4, GEN 1044
Target
5T4 x CD3
Action
modulators, stimulants
Mechanism
5T4 modulators(Trophoblast glycoprotein modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]
Active Indication-
Inactive Indication
Bladder CancerEsophageal CarcinomaMetastatic Solid Tumor+ [5]
Originator Organization
Genmab A/SGenmab A/S
Active Organization-
Inactive Organization
Genmab, Inc.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with GEN-1044
NCT04424641
/ TerminatedPhase 1/2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1044 in Subjects With Malignant Solid Tumors
100 Clinical Results associated with GEN-1044
Login to view more data
100 Translational Medicine associated with GEN-1044
Login to view more data
100 Patents (Medical) associated with GEN-1044
Login to view more data
100 Deals associated with GEN-1044
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 2
United States
Genmab, Inc.
15 Jul 2020
Bladder CancerPhase 2
Denmark
Genmab, Inc.
15 Jul 2020
Bladder CancerPhase 2
Israel
Genmab, Inc.
15 Jul 2020
Bladder CancerPhase 2
Spain
Genmab, Inc.
15 Jul 2020
Esophageal CarcinomaPhase 2
United States
Genmab, Inc.
15 Jul 2020
Esophageal CarcinomaPhase 2
Denmark
Genmab, Inc.
15 Jul 2020
Esophageal CarcinomaPhase 2
Israel
Genmab, Inc.
15 Jul 2020
Esophageal CarcinomaPhase 2
Spain
Genmab, Inc.
15 Jul 2020
Metastatic Solid TumorPhase 2
United States
Genmab, Inc.
15 Jul 2020
Metastatic Solid TumorPhase 2
Denmark
Genmab, Inc.
15 Jul 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04424641 (first-in-human clinical trial, CTgov)
Phase 1/2
Esophageal Carcinoma | Metastatic Solid Tumor | Squamous Cell Carcinoma of Head and Neck ...
View more
48
(GEN1044 Doses 0.3/3/3 mg)
hnapaingzp = kzmbyejmgi cyzelfxbsq (omqrtfvtzq, mytpsfxetb - toyagkgwla)
View more
-
01 Feb 2023
(GEN1044 Doses 1/3/10 mg)
hnapaingzp = njtusrktlw cyzelfxbsq (omqrtfvtzq, niyklavhxn - zcurwjsvkc)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free